Latent Labs

aid: latent-labs
name: Latent Labs
description: Latent Labs is a London- and San Francisco-based frontier AI lab founded in 2023 by Dr. Simon Kohl, a former
  senior research scientist on DeepMind's Nobel Prize-winning AlphaFold 2 and co-lead of DeepMind's protein design team. The
  company builds generative AI foundation models to make biology programmable, with the goal of enabling biotech and pharmaceutical
  partners to computationally generate and optimize therapeutic molecules. Latent Labs emerged from stealth in February 2025
  with $50M in total funding ($40M Series A co-led by Radical Ventures and Sofinnova Partners, plus 8VC, Kindred Capital,
  Pillar VC, Flying Fish, Isomer, and angel investors including Jeff Dean, Aidan Gomez, and Mati Staniszewski). The company's
  proprietary model family includes Latent-X (atom-level de novo protein binder design for macrocycles and mini-binders),
  Latent-X2 (drug-like antibodies with low ex vivo immunogenicity), and Latent-Y (described as the first lab-validated agent
  for drug design). Models are accessed through the Latent Labs Platform (platform.latentlabs.com) — a no-code web application
  with a free tier and daily credits — and, for Latent-X2, via API for commercial partners. There is no public OpenAPI spec,
  SDK, or open-source release at this time; programmatic access is gated through partnerships@latentlabs.com and wet-lab validation
  is performed in-house at the company's San Francisco facility.
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/latent-labs.png
tags:
- Artificial Intelligence
- Generative AI
- Foundation Models
- Biology
- Programmable Biology
- Protein Design
- Drug Discovery
- Drug Design
- Antibodies
- Macrocycles
- Protein Binders
- Biotech
- Pharmaceutical
- Life Sciences
- AlphaFold
- Computational Biology
url: https://raw.githubusercontent.com/api-evangelist/latent-labs/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/latent-labs-domain-security.yml
- type: Website
  url: https://www.latentlabs.com
- type: Platform
  url: https://platform.latentlabs.com
- type: Documentation
  url: https://docs.latentlabs.com
- type: GettingStarted
  url: https://docs.latentlabs.com/docs/getting-started
- type: Tutorials
  url: https://docs.latentlabs.com/docs/tutorials
- type: Troubleshooting
  url: https://docs.latentlabs.com/docs/troubleshooting
- type: ChangeLog
  url: https://docs.latentlabs.com/changelog/friday-1-august-2025
- type: LatentY
  url: https://www.latentlabs.com/latent-y/
- type: LatentX2
  url: https://www.latentlabs.com/latent-x2/
- type: LatentX
  url: https://www.latentlabs.com/latent-x/
- type: Team
  url: https://www.latentlabs.com/team/
- type: Press
  url: https://www.latentlabs.com/press-category/latent-labs/
- type: TermsOfService
  url: https://docs.latentlabs.com/docs/terms-data-security-privacy
- type: PrivacyPolicy
  url: https://docs.latentlabs.com/docs/privacy-policy
- type: License
  url: https://docs.latentlabs.com/docs/user-license-agreement-1
- type: AcceptableUse
  url: https://docs.latentlabs.com/docs/prohibited-use-policy
- type: CookiePolicy
  url: https://docs.latentlabs.com/docs/cookie-policy
- type: Contact
  url: mailto:contact@latentlabs.com
- type: Partnerships
  url: mailto:partnerships@latentlabs.com
- type: Twitter
  url: https://x.com/latent_labs
- type: LinkedIn
  url: https://www.linkedin.com/company/latent-labs
- type: Bluesky
  url: https://bsky.app/profile/latentlabs.bsky.social
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com